45 CFR § 180 compliance
A · 100
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
2,108
Insurances with rates
25
CPT / HCPCS codes
1,862
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| A9616 | GALLIUM-68 GOZETOTIDE (GOZELLIX) 25 MCG INTRAVENOUS SOLUTION | $1,629,875 | $977,925 | $1,171 | $1,629,875 | 71 |
| 579 | OTHER SKIN, SUBCUTANEOUS TISSUE AND BREAST PROCEDURES WITH MCC | $223,502 | $134,101 | $1,011 | $223,502 | 73 |
| A9800 | GALLIUM-68 GOZETOTIDE (ILLUCCIX) 25 MCG INTRAVENOUS SOLUTION | $168,919 | $101,351 | $363 | $146,960 | 71 |
| J9347 | TREMELIMUMAB-ACTL 20 MG/ML INTRAVENOUS SOLUTION | $167,566 | $100,540 | $143 | $237,227 | 74 |
| A9607 | LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN 27 MCI/ML (1,000 MBQ/ML) IV SOLN | $150,946 | $90,568 | $259 | $133,872 | 74 |
| 827 | MYELOPROLIFERATIVE DISORDERS OR POORLY DIFFERENTIATED NEOPLASMS WITH MAJOR O.R. PROCEDURES WITH CC | $146,901 | $88,140 | $15,643 | $146,901 | 73 |
| J9298 | NIVOLUMAB 240 MG-RELATLIMAB-RMBW 80 MG/20 ML INTRAVENOUS SOLUTION | $132,037 | $79,222 | $202 | $178,388 | 74 |
| 799 | SPLENIC PROCEDURES WITH MCC | $123,253 | $73,952 | $1,011 | $136,172 | 61 |
| J2507 | PEGLOTICASE 8 MG/ML INTRAVENOUS SOLUTION | $117,716 | $70,630 | $3,769 | $166,702 | 74 |
| J0202 | ALEMTUZUMAB 12 MG/1.2 ML INTRAVENOUS SOLUTION | $98,538 | $59,123 | $2,447 | $162,360 | 74 |
| J3357 | USTEKINUMAB 90 MG/ML SUBCUTANEOUS SYRINGE | $95,998 | $57,599 | $21,119 | $83,518 | 45 |
| 331 | MAJOR SMALL AND LARGE BOWEL PROCEDURES WITHOUT CC/MCC | $95,856 | $57,513 | $1,011 | $95,856 | 74 |
| 329 | MAJOR SMALL AND LARGE BOWEL PROCEDURES WITH MCC | $94,984 | $56,990 | $1,011 | $144,799 | 73 |
| 619 | O.R. PROCEDURES FOR OBESITY WITH MCC | $94,478 | $56,687 | $18,579 | $94,478 | 73 |
| 981 | EXTENSIVE O.R. PROCEDURES UNRELATED TO PRINCIPAL DIAGNOSIS WITH MCC | $89,854 | $53,912 | $1,011 | $127,951 | 62 |
| 870 | SEPTICEMIA OR SEVERE SEPSIS WITH MV >96 HOURS | $88,563 | $53,138 | $1,011 | $255,146 | 74 |
| 239 | AMPUTATION FOR CIRCULATORY SYSTEM DISORDERS EXCEPT UPPER LIMB AND TOE WITH MCC | $88,213 | $52,928 | $1,011 | $141,982 | 73 |
| 856 | POSTOPERATIVE OR POST-TRAUMATIC INFECTIONS WITH O.R. PROCEDURES WITH MCC | $85,787 | $51,472 | $8,107 | $108,319 | 73 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $83,216 | $49,929 | $137 | $105,868 | 74 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $80,818 | $48,491 | $59.32 | $98,394 | 74 |
| 157 | DENTAL AND ORAL DISEASES WITH MCC | $77,284 | $46,370 | $1,011 | $77,284 | 73 |
| 908 | OTHER O.R. PROCEDURES FOR INJURIES WITH CC | $71,083 | $42,650 | $1,011 | $71,083 | 73 |
| 616 | AMPUTATION OF LOWER LIMB FOR ENDOCRINE, NUTRITIONAL AND METABOLIC DISORDERS WITH MCC | $69,609 | $41,765 | $1,011 | $134,390 | 74 |
| J9026 | TARLATAMAB-DLLE 10 MG INTRAVENOUS SOLUTION | $64,842 | $38,905 | $1,567 | $86,617 | 74 |
| 488 | KNEE PROCEDURES WITHOUT PRINCIPAL DIAGNOSIS OF INFECTION WITH CC/MCC | $63,434 | $38,060 | $10,884 | $63,434 | 73 |
| C1874 | GRAFT ENDOVASC ZENITH ALPHA THORACIC DISTAL | $63,000 | $37,800 | $13,860 | $63,000 | 296 |
| 330 | MAJOR SMALL AND LARGE BOWEL PROCEDURES WITH CC | $61,611 | $36,966 | $1,011 | $98,229 | 73 |
| 183 | MAJOR CHEST TRAUMA WITH MCC | $61,178 | $36,707 | $1,011 | $61,178 | 73 |
| J9043 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $61,166 | $36,699 | $231 | $76,566 | 74 |
| J1628 | GUSELKUMAB 200 MG/20 ML (10 MG/ML) INTRAVENOUS SOLUTION | $60,414 | $36,249 | $72.94 | $80,657 | 74 |
| 326 | STOMACH, ESOPHAGEAL AND DUODENAL PROCEDURES WITH MCC | $58,957 | $35,374 | $1,011 | $114,055 | 73 |
| 854 | INFECTIOUS AND PARASITIC DISEASES WITH O.R. PROCEDURES WITH CC | $58,541 | $35,124 | $1,011 | $67,586 | 74 |
| 570 | SKIN DEBRIDEMENT WITH MCC | $56,990 | $34,194 | $1,011 | $71,205 | 73 |
| 821 | LYMPHOMA AND LEUKEMIA WITH MAJOR O.R. PROCEDURES WITH CC | $56,319 | $33,791 | $13,893 | $103,223 | 73 |
| 165 | MAJOR CHEST PROCEDURES WITHOUT CC/MCC | $56,314 | $33,789 | $1,011 | $87,766 | 74 |
| C1876 | STENT ZENITH DISSECTION ENDOVASCULAR ZDES- 36-120-US | $56,000 | $33,600 | $12,320 | $56,000 | 74 |
| 559 | AFTERCARE, MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE WITH MCC | $55,832 | $33,499 | $250 | $68,598 | 73 |
| 041 | PERIPHERAL, CRANIAL NERVE AND OTHER NERVOUS SYSTEM PROCEDURES WITH CC OR PERIPHERAL NEUROSTIMULATOR | $55,370 | $33,222 | $1,011 | $80,380 | 73 |
| 853 | INFECTIOUS AND PARASITIC DISEASES WITH O.R. PROCEDURES WITH MCC | $55,353 | $33,212 | $1,011 | $122,574 | 73 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $53,199 | $31,919 | $268 | $74,213 | 74 |
| 350 | INGUINAL AND FEMORAL HERNIA PROCEDURES WITH MCC | $51,420 | $30,852 | $1,011 | $70,517 | 73 |
| 354 | HERNIA PROCEDURES EXCEPT INGUINAL AND FEMORAL WITH CC | $51,176 | $30,705 | $1,011 | $57,915 | 74 |
| J9022 | ATEZOLIZUMAB 1,200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $50,352 | $30,211 | $93.91 | $62,307 | 74 |
| 605 | TRAUMA TO THE SKIN, SUBCUTANEOUS TISSUE AND BREAST WITHOUT MCC | $50,330 | $30,198 | $1,011 | $50,330 | 73 |
| 15273 | App Skn Subgrft T/a/L Area/100sq Cm 1st 100sq Cm | $49,170 | $29,502 | $2,067 | $42,778 | 74 |
| 15274 | App Skn Sub Grft T/a/L Area>/=100scm Adl 100sqcm | $49,170 | $29,502 | $125 | $42,778 | 74 |
| 620 | O.R. PROCEDURES FOR OBESITY WITH CC | $47,499 | $28,500 | $10,830 | $51,419 | 73 |
| 602 | CELLULITIS WITH MCC | $47,398 | $28,439 | $1,011 | $47,398 | 73 |
| J9144 | DARATUMUMAB 1,800 MG-HYALURONIDASE-FIHJ 30,000 UNIT/15 ML SUBCUT SOLN | $47,164 | $28,298 | $55.06 | $54,797 | 74 |
| J1640 | HEMIN 350 MG INTRAVENOUS POWDER FOR SOLUTION | $46,972 | $28,183 | $10,334 | $30,532 | 24 |
Showing top 50 of 2,108 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.